Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, Wisconsin.
Department of Pharmacology, Medical College of Wisconsin, Milwaukee, Wisconsin.
J Tissue Eng Regen Med. 2019 Feb;13(2):244-252. doi: 10.1002/term.2785. Epub 2019 Jan 4.
The contents of platelet α-granules arrive via a number of pathways; some are synthesized by megakaryocytes (MKs), for example, von Willebrand factor (VWF), whereas others are endocytosed from plasma, for example, fibrinogen (Fgn) and factor V (FV). Currently, almost all in vitro-induced pluripotent stem cell (iPSC)-derived MKs are generated under serum-free conditions, and their α-granule cargoes lack components that would normally be taken up from plasma during the course of megakaryopoiesis. How this might affect the ability of in vitro-derived platelets to contribute fully to haemostasis is not known. The purpose of this investigation was to examine whether "feeding" human plasma to iPSC-derived MKs might result in loading their α-granules with physiologically important proteins. iPSCs were differentiated to CD41 /CD42b MKs using a serum-free protocol. The resulting MKs were polyploid, expressed a number of platelet-specific surface receptors, and spread on Fgn or collagen-coated surfaces. Reverse transcription-polymerase chain reaction analysis detected mRNA transcripts for FV and VWF but not Fgn chains. Fluorescence immunocytochemistry and confocal microscopy confirmed constitutive VWF distribution in granule-like structures in MKs cultured under plasma-free conditions, and the granules became positive for Fgn upon incubation with human plasma. iPSC-derived MKs showed a low level of constitutive FV expression that increased dramatically upon incubation with human plasma. Taken together, these data suggest that human iPSC-derived MKs are capable of endocytosing and storing plasma components in their α-granules. Incorporating this methodology into current protocols for producing in vitro-derived MKs should provide novel insights into MK biology and lead to the generation of large numbers of MKs and platelets with improved functionality.
血小板α 颗粒的内容物通过多种途径到达;有些是由巨核细胞(MK)合成的,例如血管性血友病因子(VWF),而另一些则是从血浆内吞的,例如纤维蛋白原(Fgn)和因子 V(FV)。目前,几乎所有无血清条件下体外诱导多能干细胞(iPSC)衍生的 MK 都是在无血清条件下生成的,它们的α 颗粒货物缺乏在巨核细胞生成过程中通常从血浆中摄取的成分。这将如何影响体外衍生血小板充分参与止血的能力尚不清楚。本研究旨在探讨向 iPSC 衍生的 MK 中添加人血浆是否会导致其α 颗粒装载生理上重要的蛋白质。iPSC 使用无血清方案分化为 CD41/CD42b MK。由此产生的 MK 是多倍体,表达了许多血小板特异性表面受体,并在 Fgn 或胶原蛋白涂层表面上扩散。逆转录-聚合酶链反应分析检测到 FV 和 VWF 的 mRNA 转录本,但没有 Fgn 链。荧光免疫细胞化学和共聚焦显微镜证实,在无血浆条件下培养的 MK 中,VWF 分布在颗粒状结构中,并且在用人血浆孵育后,颗粒对 Fgn 呈阳性。iPSC 衍生的 MK 表现出低水平的组成性 FV 表达,在用人血浆孵育后显着增加。综上所述,这些数据表明,人 iPSC 衍生的 MK 能够内化和储存其α 颗粒中的血浆成分。将这种方法纳入当前生产体外衍生 MK 的方案中,应能深入了解 MK 生物学,并生成具有改善功能的大量 MK 和血小板。